CDKN2A and sarcoma: The comprehensive genomic analysis via The Cancer Genome Atlas (TCGA) has shown that approximately one quarter of all sarcomas harbor genetic alterations in the Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) - Cyclin D (CCND) - CDK4 - retinoblastoma (RB) axis (15, 16), providing strong rationale for targeting this crucial pathway in sarcomas.